Wuhan YZY Biopharma Co Ltd (2496.HK) Comparison with companies in other sectors?

Wuhan YZY Biopharma Co Ltd has a share price of 198.00M. You can analyze Wuhan YZY Biopharma Co Ltd (2496.HK) competitors across different market sectors through stock heatmaps.

What are 2496.HK's NET and operating margins?

Wuhan YZY Biopharma Co Ltd (2496.HK) operating margin is around -32.32, and net profit margin is approximately -33.31 as of the latest reports.

In what way does 2496.HK's earnings per share (EPS) trend reflect its financial momentum?

Wuhan YZY Biopharma Co Ltd (2496.HK) EPS is -0.55 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Wuhan YZY Biopharma Co Ltd is -10.18, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Wuhan YZY Biopharma Co Ltd?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Wuhan YZY Biopharma Co Ltd like P/E which is -5.50, P/B which is 32.64, and PEG which is -0.36. Compare them with sector averages to evaluate if the stock is priced fairly.

Wuhan YZY Biopharma Co Ltd

2496.HK•HKSE

Healthcare

Biotechnology

HK$5.60

HK$-0.12(-2.10%)

Wuhan YZY Biopharma Co Ltd (2496.HK) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.55

P/E Ratio

-10.18

ROE

-3.00%

Net Margin

-33.31%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$1.11B

Shares OutstandingTotal number of shares issued

$198.00M

Book Value/ShareNet worth per share

$0.16

Revenue/ShareAnnual revenue per share

$0.03

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.55

Net MarginNet income as percentage of revenue

-3331.01%

Operating MarginOperating income as percentage of revenue

-3231.69%

ROEReturn on shareholders' equity

-300.21%

ROAReturn on total assets

-67.68%

ROCEReturn on capital employed

-215.24%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.60

Cash/ShareCash and equivalents per share

$0.65

FCF YieldFree cash flow as percentage of market cap

-11.40%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 2496.HKFinancial Ratios Analysis details for 2496.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 2496.HKSector Benchmarking details for 2496.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Wuhan YZY Biopharma Co Ltd Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Wuhan YZY Biopharma Co Ltd. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Wuhan YZY Biopharma Co Ltd's unique business strengths and challenges.

Key Financial Metrics for Wuhan YZY Biopharma Co Ltd

For Wuhan YZY Biopharma Co Ltd, essential financial indicators include EPS -0.55, PE -10.18, and ROE -3.00. These key ratios reveal insights into Wuhan YZY Biopharma Co Ltd's profitability, valuation, and operational health. Understanding these metrics enables you to compare Wuhan YZY Biopharma Co Ltd with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Wuhan YZY Biopharma Co Ltd

Metrics like Net Margin -3331.01% and ROA -67.68% shed light on how well Wuhan YZY Biopharma Co Ltd is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Wuhan YZY Biopharma Co Ltd can sustain its operations and continue growing in the future.

Valuation and Market Position of Wuhan YZY Biopharma Co Ltd

Using ratios such as P/B Ratio 32.64 and PEG Ratio -0.36, investors can assess whether Wuhan YZY Biopharma Co Ltd is appropriately valued based on its financials and growth potential. These figures, combined with Wuhan YZY Biopharma Co Ltd's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Wuhan YZY Biopharma Co Ltd

Financial health indicators, such as Debt/Equity Ratio 4.17 and Cash Flow $-0.60, provide a snapshot of Wuhan YZY Biopharma Co Ltd's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Wuhan YZY Biopharma Co Ltd, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Wuhan YZY Biopharma Co Ltd

Investing in Wuhan YZY Biopharma Co Ltd based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Wuhan YZY Biopharma Co Ltd focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;